Familial Amyloid Cardiomyopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Familial Amyloid Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid cardiomyopathy (ATTR-CM), results from the aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart. TTR is usually circulated as a homo-tetramer; however, in FAC patients, TTR dissociates and misassembles into amyloid fibrils that are insoluble and resistant to degradation. Due to this resistance to degradation, when amyloid fibrils accumulate in the heart’s walls, specifically the left ventricle, causing rigidity that prevents the heart from properly relaxing and refilling with blood. This is called diastolic dysfunction and can further lead to heart failure.
The Familial Amyloid Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Familial Amyloid Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Amyloid Cardiomyopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Familial Amyloid Cardiomyopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Familial Amyloid Cardiomyopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Familial Amyloid Cardiomyopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Familial Amyloid Cardiomyopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alexion Pharmaceuticals IncAlnylam Pharmaceuticals Inc
BridgeBio Pharma Inc
BSIM Therapeutics SA
Corino Therapeutics Inc
Covalent Bioscience Inc
Ionis Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Familial Amyloid Cardiomyopathy reports